Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Scores of Overseas Midwives Hired By NHS To Aid New Mothers

Scores of Overseas Midwives Hired By NHS To Aid New Mothers

Under the gamut of the new NHS England initiative, up to 500 additional midwives from all over the world will join maternity services across the country.

Midwives from India, Jamaica, Zimbabwe, Italy, and the Philippines have already been hired as part of the NHS’s Maternity Workforce Programme and its innovative Maternity International Recruitment Program to assist mothers, babies, and families at 80 NHS trusts. The NHS Chief Midwifery Officer for England, Professor Jacqueline Dunkley-Bent, has welcomed the new hires and complimented their other midwives and staffers in maternity services throughout the nation for their diligent work supporting new and expectant families during the COVID-19 pandemic.

Professor Dunkley-Bent OBE, England’s Chief Midwifery Officer, said: Their midwives and maternity service support staff perform a tremendously important part of caring for millions of women, infants, and family members each year, and they have worked extremely hard all through the pandemic to make sure family members have direct exposure to the customised care and support they need.

Internationally trained midwives, like the Windrush generation, have been a vital part of the midwifery family almost since the NHS was established, and she is thrilled that approximately 500 overseas midwives will be embracing the profession in the coming six months.

On a national scale, the NHS is creating a variety of strategies to continually improve services for women and babies, which include developing methods to enhance the count of domestically trained midwives as well as enhancing global recruitment, with each new recruit bringing a wealth of skills, expertise, and experience to the services. They would like the NHS to be the safest place in the world to give birth, and these new international midwives will help them accomplish that goal, so she thereby thanked them and welcomed them to the group.

At various stages, the new midwives will join the NHS’s 22,172-strong midwifery staff. More than 30 midwives have arrived since December 2021, with hundreds more due in the next six months. A complete medical induction and psychological support will be provided to each new midwife. Then they’ll start providing support and care to the moms and infants in their trust. The initiative builds on NHS England and NHS Improvement’s current foreign nursing recruitment programme, which hired 21,000 nurses from September 2019 to March 2021.

T’Asia Dallas is one of the new international midwives. Ms. Dallas, a Jamaican native, has joined the Rosie Maternity Hospital at Cambridge University Hospitals. The NHS ideals and the number of chances are intriguing, Ms Dallas said. There is always upward progression for midwives. She decided to live and serve in the United Kingdom in order to strengthen her midwifery abilities and widen her skills.

She wanted to be a part of blending healthy women and children into society and hence decided to become a midwife. Women and children who are healthy help build strong families and societies, which lets people reach their full positive potential.

NHS leaders have allocated ยฃ4.5 million to assist with the new initiative, which is part of the healthcare service’s larger continuous aim to boost maternity care. Over the next year, the NHS will invest ยฃ127 million in maternity services throughout England to help provide better and much more individualised care for women, babies, and families, as well as to address issues revealed by the Ockenden Review.

Undertaking ethical recruiting and offering a variety of stimulus programmes to hospitals and overseas midwives are key considerations for the NHS’s programme. During COVID-19, NHS England and NHS Improvement examined current issues surrounding NHS maternity care in England. Since the start of the COVID-19 pandemic, NHS maternity services have reportedly delivered almost 1,500 infants every day, averaging one delivery every 54 seconds. Midwives provided a first midwife consultation every 41 seconds in March 2021. Between December 31, 2020 and December 31, 2021, 3,239 midwives are said to have entered NHS hospital and community health services.

42 Local Maternity Systems across the UK are pulling together local health organisations, doctors, and families to ensure that maternity services fit the requirements of their communities, leading to sustained outcomes for patients and experiences as part of the NHS Long Term Plan.

Anybody enthusiastic about becoming a midwife can discover more by browsing for NHS jobs online.

The FDA Has Imposed Restrictions On J&J COVID-19 Vaccine

The US Food and Drug Administration recently announced that the Johnson & Johnson/Janssen COVID-19 vaccine’s urgent use permit will be restricted to people 18 or older for whom other vaccines are really not suitable or available, as well as those who choose Johnson & Johnson because they might not otherwise get inoculated.

The FDA highlighted in a statement that the change was made due to the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare and hazardous clotting disorder that can occur after getting the vaccination.

Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement that they have been closely monitoring the Janssen COVID-19 Vaccine and the onset of TTS after its administration and used the latest information from their safety surveillance systems to reassess the EUA. They acknowledge that the Janssen COVID-19 Vaccine continues to play an important role in the ongoing pandemic fight in the United States and around the world. The latest decision underscores the dependability of the safety surveillance systems and their dedication to making decisions based on scientific data.

The amended permission also extends to booster doses, according to the FDA.

For certain patients, the FDA has judged that the advantages of the Johnson & Johnson vaccine exceed the dangers. The following people may still receive the vaccine-

  • People who have experienced a severe adverse reaction to an mRNA vaccine from Pfizer/BioNTech or Moderna
  • Those who would stay unvaccinated without the Johnson & Johnson vaccination due to personal reservations about mRNA vaccines
  • People who don’t have accessibility to mRNA COVID-19 vaccinations

According to the US Centers for Disease Control and Prevention, more than 18.7 million doses of the Johnson & Johnson vaccine had been provided in the US as of May 5th. 7.7% of those who are deemed completely inoculated received this vaccination. The CDC’s vaccine advisory committee updated its recommendation on Johnson & Johnson’s vaccine after a meeting in December, stating it makes a preferable suggestion for the use of mRNA COVID-19 vaccines well over Janssen adenoviral-vectored COVID-19 vaccine in all individuals aged 18 years or older in the United States.

The committee had the same reservations about TTS.

The CDC and the FDA had previously advised against using this vaccination due to TTS incidents. The suspension was lifted, but with a warning regarding the unusual clotting instances.

Johnson & Johnson said at the time in a statement that their top goal is the protection and well-being of those who use their products. A very rare illness involving blood clots and low platelets has been reported in a tiny percentage of people who have gotten their COVID-19 vaccination. They have been collaborating closely with medical specialists and health officials, and they strongly believe that this knowledge should be made available to healthcare professionals and the public.

The FDA claims that 15% of TTS episodes are deadly in a revised fact sheet on the vaccination.

Cases reported to the Vaccination Adverse Events Reporting System (VAERS) network until March 18 are included in the agency’s latest review of the vaccine. The FDA reports that 60 cases of TTS have been verified, including nine deaths.

TTS is exceedingly uncommon, with just about three occurrences per million vaccination doses delivered. TTS has been found to be most common in women aged 30 to 49. Women in this age group have had about eight cases per million vaccination doses delivered.

TTS symptoms typically emerge one or two weeks post vaccination. Difficulty breathing, chest pain, swelling of legs, chronic abdomen pain, neurological symptoms such as headaches or confused vision, or red spots just deep within the skin called petechiae outside the immunisation site are all possible occurences.

The Janssen COVID-19 vaccine can induce thrombosis with thrombocytopenia syndrome (TTS), which can be life-threatening, according to a new warning on the vaccine’s fact sheet.

3 Things to Know About Probiotic Supplements

3 Things to Know About Probiotic Supplements

Probiotics are โ€œgoodโ€ bacteria that you can introduce to your gut microbiome to maintain digestive health and strengthen your immune system. The name derives from the Greek words pro biota, meaning โ€œfor lifeโ€. The name itself thus has positive connotations.

You can get probiotics from food sources such as yogurt, kefir, kombucha, pickles, kimchi, and other fermented foods. Alternatively, you can find them in the form of dietary supplements. Probiotics have many health benefits, but how to know if you need to take any? Which supplements or foods to consume? How often should you consume them? Can you overdose on probiotics? These are valid questions that everyone should consider.

Here are three essential things to know about probiotic supplements.

1. Probiotics Promote Gut Health

Your gut microbiome is populated by a collection of various bacteria and other microorganisms. Poor nutrition, stress, and infections can cause an imbalance in the microbiome. In these conditions, harmful bacteria proliferate. When your gut microbiome becomes unbalanced, you experience heightened health risks or digestive problems such as constipation, gas, or bloating.

Since theyโ€™re good bacteria, probiotics can restore the balance in your gut microbiome and promote gut health. By taking probiotics, you repopulate your microbiome with beneficial microorganisms.

2. Side Effects Are Rare or Negligible

Taking probiotic supplements is very safe for the majority of the population. There are few side effects associated with probiotics. Thirst, gas, bloating, and constipation are the most common side effects. However, it is important to acknowledge that probiotic supplements are dietary supplements, so they donโ€™t require approval from the Food & Drug Administration.

Theoretically, probiotic supplements are very safe with minimal, if any, side effects. But supplements are not as stringently evaluated and heavily researched as drugs. As a consumer, you have to research the supplements you buy.

As long as you buy your probiotic supplements from reliable brands that sell what they advertise, you can take probiotics without worries. If you are not sure what probiotics are right for you, ask your doctor for recommendations.

3. There Are Different Types of Supplements

Each probiotic supplement contains specific strains of bacteria, so choosing the right supplement is critical. If your gut lacks a beneficial bacteria, you want the specific strain your microbiome is lacking. You donโ€™t want to add more of the same strain of bacteria that dominates your microbiome.

Taking advantage of the many health benefits of probiotics is only possible if you find the right supplement for you. At the same time, taking the right supplement over a long period can also be detrimental to your gut health. You will have too much of the same strain of bacteria in your gut. For a healthy microbiome, avoid overpopulation of the same bacteria. Diversity is key.

If you have any reason to worry about your gut health, consider giving probiotics a chance. They can help you overcome many gut-related health problems. Whether you prefer to consume foods rich in probiotics or take supplements, ask your doctor for advice in advance.

Abbott launches HBsAg Next Assay in India to accelerate early and enhanced detection of hepatitis B

Abbott launches HBsAg Next Assay in India to accelerate early and enhanced detection of hepatitis B

Global healthcare leader Abbott has announced the launch of the HBsAg Next Qualitative solution in India to enhance detection of the hepatitis B virus (HBV). This assay will help improve patient outcomes while maintaining safe blood supplies. This highly sensitive chemiluminescent microparticle immunoassay (CMIA) assists in the early and enhanced detection of HBV in human serum and plasma (blood) samples and in population screening. A chemiluminescent immunoassay is a variation of the standard enzyme immunoassay, a biochemical technique used in immunology.

Early identification of HBV infections allows patients to receive the necessary care to prevent or delay progression of advanced liver diseases. Moreover, it also reduces the risk of transmission.

The HBsAg Next Qualitative assay is an advanced, next generation solution to better support the earlier detection of HBV. It detects HBV surface antigen (HBsAg) in human serum and plasma. Moreover, it overcomes traditional challenges by showcasing the highest level of assay performance required to detect infection in immunocompromised groups.

Dr. Jaganathan Sickan, senior associate director, medical affairs, Core Diagnostics at Abbott said, โ€œIn India, Hepatitis B screening is vital since it is vastly under-diagnosed. With HBsAg Next qualitative assay, laboratories in India can now detect HBV earlier than ever. This will help physicians identify at risk patients sooner, which in turn leads to early treatment and care. This assay represents the next generation of HBV diagnostic performance and will enhance our comprehensive infectious disease portfolio.โ€

Hepatitis B is a liver infection caused by hepatitis B virus. It can be acute or chronic, with chronic cases potentially leading to liver failure, cirrhosis, or liver cancer. About 296 million people worldwide currently live with chronic hepatitis B, with 10 to 15 per cent of the worldโ€™s HBV carriers (40 million) found in India alone. Moreover, co-infections with HIV are also prevalent, with roughly 1 in 10 people living with HIV estimated to have hepatitis B. However, hepatitis B virus is often silently undiagnosed, with only 10.5 per cent of all people estimated to be living with hepatitis B aware of their condition.

Dr. Ekta Gupta, Professor, In-Charge, Department of Clinical Virology, ILBS, New Delhi, said, โ€œThe national burden of hepatitis B is significant but due to the extremely low rate of diagnosis in India, we are unaware of the actual situation. This assay not only aids in earlier detection of the infection, it reduces the risks of undetected virus. With such highly sensitive qualitative assays, doctors will be able to identify at-risk patients and provide appropriate treatment sooner.โ€

With the HBsAg Next Qualitative Solution, laboratories can now better detect, analyze the infection and reduce the risks of undetected virus, have a consistent detection of all HBV genotypes and enhance detection and confirmation of mutants. Additionally, it can detect HBV in specimens on Abbottโ€™s Alinity i or ARCHITECT systems. Testing for HBV can be performed for diagnostic purposes, as a screening test, or even after death (post-mortem) to prevent HBV spread to recipients of blood, blood components, cells, tissues, and organs.

Dr. John Fletcher, Professor, Dept of Clinical Virology, CMC Vellore commented, โ€œCMCโ€™s commitment to screen HBsAg started around the 1970s and we continue to embrace the state-of-the-art technologies and chemistries. HBV identification involves overcoming several obstacles like window identification, detection of mutants, occult infections, breakthrough infections and reactivations.

Next generation HBsAg assays with superior performance characteristics can enhance stringent early detection and identification of challenging phases of HBV infections as well as efficient monitoring of functional cure. Cumulatively, these benefits converge to significantly reduce the risk of transmission and overall improve the global continuum of care by reducing the pernicious first gap.โ€

The World Health Organization (WHO) has set targets to eliminate viral hepatitis as a public health concern by 2030 to reduce infection incidence and related complications. Effective diagnostic solutions for early and accurate diagnosis can help achieve these goals. The HBsAg Next assay, with better sensitivity and specificity, will help India advance towards its goals of HBV diagnostics and care.

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer in Europe

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced   Hormone-Sensitive Prostate Cancer in Europe

Myovant Sciencesย  and Accord Healthcare, Ltd.ย  announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.

Under the terms of the agreement, Myovant will receive an upfront payment of $50 million and is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million. In addition, Myovant is eligible to receive tiered royalties from the high-teens to mid-twenties on net sales. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.

โ€œWeโ€™re delighted to join forces with Accord to make available the first and only oral androgen deprivation therapy for men with advanced hormone-sensitive prostate cancer in Europe,โ€ said David Marek, Chief Executive Officer of Myovant. โ€œAccord has a longstanding commitment to oncology with proven commercial capabilities that they will leverage to accelerate the launch to reach more patients with this meaningful therapy.โ€

โ€œWe are proud to launch ORGOVYX in Europe, as an addition to our specialty brand offerings,โ€ said Binish Chudgar, Managing Director of Accord. โ€œAccord currently supplies around 1 in 3 injectable oncology medicines in Europe and this agreement underpins our commitment to patients with cancer and our continued investment in novel therapies. With over 1.9 million men living with prostate cancer in Europe, our partnership with Myovant will provide men living with hormone-sensitive advanced prostate cancer a new oral treatment option.โ€

On April 29, 2022, the European Commission approved the marketing authorization application for ORGOVYX (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer. The decision applies to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. The marketing authorization application for ORGOVYX is pending review by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). Accord expects to launch ORGOVYX in Europe in the second half of calendar year 2022.

Goldman Sachs & Co. LLC has acted as the exclusive financial advisor to Myovant and Sidley Austin LLP represented Myovant in the transaction.

About Prostate Cancer
In 2020, the total number of men in Europe with prostate cancer was approximately 1.9 million according to the World Health Organization Agency for Cancer Research WHO IntlAgencyCancerResearch PC.

Philips receives FDA clearance for latest breakthrough high-performance MR 7700 system

Philips receives FDA clearance for latest breakthrough high-performance MR 7700 system

Royal Philips, a global leader in health technology, announced it has received FDA 510(k) clearance for the company new MR 7700 3.0T MR system. This latest break-through MR innovation from Philips delivers unmatched performance and precision for both research and advanced clinical diagnostics, helping to address the Quadruple Aim. The XP gradients of MR 7700 provide high accuracy to support a confident diagnosis for every patient with Philipsโ€™ highest quality diffusion imaging and advanced neuroscience, supporting improved patient care and lower costs. MR 7700 expands scanning capabilities with a fully integrated multi-nuclei imaging and spectroscopy solution to explore new clinical pathways, without sacrificing clinical imaging workflow or wide-bore patient comfort, to enhance the experience of both staff and patients.

With the easy to use interface of the MR 7700, scientists and clinicians can now access the scanner without compromising workflow. Driven by seamless integration of multi-nuclei capabilities, the new MR 7700 allows radiologists to image six different clinically relevant nuclei across all anatomies, offering the ability to increase diagnostic confidence and add important metabolic information to MR exams to help tackle complex research programs and improve clinical decision-making to help provide improved patient care. With its AI-driven smart connected imaging, optimized workflows and integrated clinical solutions, MR 7700 helps to improve MR department productivity, enhance patient and staff experience, and deliver high quality diagnostic imaging.
Orchestrating decision-making at pivotal moments in the patientโ€™s care path journey
With all imaging protocols easily accessible via the same intuitive user-friendly interface, MR 7700 contributes to highly efficient radiology workflows and first-time-right scans. Combining high quality imaging with operational efficiency, its XP gradient coils achieve up to 35% higher signal-to-noise ratios and up to 35% shorter scan times. For clinical neurology and neuroscience, radiologists achieve 20% more fMRI volumes and 50% more diffusion tensor imaging (DTI) directions, delivering detailed high-resolution images needed to confidently identify and characterize lesions.

 

โ€œOur highly specialized team of MR physicists are very happy with the ease of use of Philips MR 7700 system, especially the implementation of new imaging protocols which is quite simple,โ€ said Prof. Walter Heindel, Professor of Radiology and Chairman of the Department of Radiology at the University Hospital Mรผnster in Germany. โ€œThe low effort required for modifying scan parameters and protocols supports fast and easy experimentation with imaging techniques. These latest features clearly help improve our patient and staff experience and distinguish Philips as one of the main reasons we choose this system.โ€
AI-driven technology helps boost neuroscience excellence
MR 7700 further demonstrates Philipsโ€™ commitment to deliver smart diagnostic systems for first-time right diagnosis through clinically relevant and intelligent diagnostics. Clinicians can leverage the MR 7700โ€™s ultra-high gradients and in-built artificial intelligence, such as its AI-driven touchless patient sensing and motion detection, to address the upswing in patient volumes already being experienced by many of todayโ€™s radiology departments. Researchers can also leverage the accuracy, power, and endurance of the MR 7700โ€™s XP gradients to help facilitate demanding research programs to boost neuroscience excellence.

โ€œEnhanced with ultra-high gradients and artificial intelligence, Philips MR 7700 is built to deliver on the high-quality clinical performance expectations of today, and to facilitate the most demanding and promising research programs that will help drive the future of MR imaging, without sacrificing workflow efficiency or wide-bore patient comfort,โ€ said Arjen Radder, General Manager of Magnetic Resonance and Diagnostic X-ray at Philips. โ€œCombined with its AI-driven smart connected imaging capabilities, optimized workflows and integrated clinical solutions help meet the quadruple aim of healthcare by improving MR department productivity, enhancing the patient and staff experience, helping to deliver high-quality diagnostic outcomes.โ€
Connecting and integrating workflows to drive clinical and operational efficiency

MR 7700 leverages the automated technology of SmartWorkflow to guide and coach where required. In addition to conventional proton magnetic resonance imaging and spectroscopy, MR 7700 has in-built MR protocols to combine proton imaging with imaging based on sodium, phosphorus, carbon, fluorine, and xenon. This multi-nuclei capability makes MR 7700 suitable for enhanced anatomical and metabolic/functional imaging in areas such as neurology, pulmonology, and oncology to help deliver fast, and confident definitive decision-making.

Via integration of a dual-tuned head coil, both multi-nuclei and conventional proton MR exams can be performed with the same coil and within the same user interface to help increase workflow efficiencies, while AI-assisted workflow solutions keep exams on schedule to help improve both patient and staff experience. Finally, with access to proactive remote monitoring, remote diagnostics and remote field support, more than 500 parameters of the MR 7700 are monitored from a distance to detect and resolve issues without impacting department operations.

Philips is debuting the MR 7700 at the International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting (May 7-12) in London, and will spotlight the new system at the upcoming European Congress of Radiology (ECR) annual congress in Vienna in July. This newest MR innovation is part of the Philips Radiology portfolio of scalable high-performance MR systems, including its latest MR 5300 1.5T helium-free in operations MR system, all of which feature intelligent software to automate tasks to help relieve the burden on busy radiology staff and departments. Philips Radiology portfolio delivers patient-centered solutions to reduce anxiety and discomfort; technologist- and radiologist-centered image processing applications for clinical and diagnostic confidence; and enterprise-integrated workflows that streamline the path to precision care.

BestRx Announces Integration with ScriptAbility

BestRx Announces Integration with ScriptAbility

BestRx is proud to announce their Pharmacy Management Software is now integrated with ScriptAbility. ScriptAbility is part of En-Vision America, Inc., a company that provides high-tech products, including a variety of accessible pharmacy labels. By forming this partnership, BestRx and ScriptAbility are helping independent pharmacies better care for patients with visual and language barriers.

ScriptAbility proudly offers the most robust and cost-effective accessible label options in the market. This includes their ScripTalk RFID-enabled talking labels, ScriptView Large Print Labels, Dual-Language Labels, Braille Labels and Controlled Substance Safety Labels (CSSL). By offering these accessible labels, pharmacies ensure all their patients can easily access and understand the dispensing instructions and safety information for their medications.

Through the new integration, BestRx pharmacies can quickly produce these labels because ScriptAbilityโ€™s easy-to-use application can be accessed directly from the pharmacy management software. Instead of having to enter the patientโ€™s information in the application, the patient and prescription details will auto populate with a few simple clicks.

โ€œIf patients donโ€™t understand their prescription labels, thereโ€™s a risk of mistakes. These mistakes can lead to hospitalization or even death,โ€ says David Raistrick, president of En-Vision America. โ€œAccessible prescription labels remove these risks and improve independence. Weโ€™re pleased to team up with BestRx. They are a proactive company that sees how accessible labels can improve medication adherence, as well as the overall quality of care for pharmacy patients.โ€

โ€œBestRx continues to identify ways to help independent pharmacies provide better patient care, while minimizing the impact on their daily workflow,โ€ says Hemal Desai, President of BestRx. โ€œThis includes ensuring patients with impairments have access to information about their medications and treatment plan. Through our integration with ScriptAbility, BestRx pharmacies can quickly produce accessible prescription labels that will not only improve medication adherence, but the overall quality of care being provided as well.

About BestRx

Founded in 1985, BestRx is proud to still be a family business. From day one, BestRx has been committed to providing independent pharmacies the tools needed to effectively care for their communities, while become more efficient and profitable. BestRx prides itself on its intuitive, easy-to-use platform, robust integrations, and unparalleled customer service. BestRx is committed to ongoing innovation to provide comprehensive support for pharmacies, now and in the years ahead, ensuring theyโ€™ll always be at the heart of growth. To learn more about BestRx, please visit: www.bestrx.com

About En-Vision America/ScriptAbility

Located in Palmetto, Florida, En-Vision America has been leveraging the latest technology to support individuals with visual impairments and language barriers for more than 25 years. This includes the development of a full suite of accessible prescription labels. Originally founded by Philip C. and David B. Raistrick in 1996, the cornerstone of the company is based upon one single premise โ€” to provide customers with greater independence and access to information through technology. To learn more about ScriptAbility, please visit: www.scriptability.com/contact-us.

HonorHealth Complete Care โ€“ first model of its kind in Arizona โ€“ opens in Surprise

HonorHealth Complete Care โ€“ first model of its kind in Arizona โ€“ opens in Surprisev

HonorHealth, a leading Valley healthcare system serving 1.6 million people in the greater Phoenix and Scottsdale area, announced the opening of their latest healthcare facility, HonorHealth Complete Care, in Surprise.

The new location at 16575 W. Waddell Road, is aย dual care retail model that provides convenient access to a full-service Emergency Room and Urgent Care under one roof. HonorHealth has partneredย withย Intuitive Healthย to build the 12,000 square-foot space that includes full X-ray, CT scan and laboratory testing capabilities.

The $12 million facility offers aย new healthcare experience that helps take the guesswork out of where to seek care when feeling ill or for an injury. Patients seeking care at an HonorHealth Complete Care facility are billed only for the level of services they receive rather than on the location of their care โ€“ saving millions of dollars in unnecessary ER visits. Additionally, by providing both urgent and emergency care under one roof, patients will benefit from reduced wait times which will allow them to get the treatment they need and get them back to their lives quicker than traditional emergency room models.

โ€œDual emergency and urgent care facilities eliminate the need for patients to self-diagnose the severity of their health concerns before selecting the most appropriate medical center for care.โ€ย said Todd LaPorte, CEO of HonorHealth.ย โ€œWe are excited to partner with Intuitive Health to bring this concept to Arizona.โ€

โ€œThis location is the first in the Valley to offer this type of care, and weโ€™re confident that this level of customer-centric service will be welcomed by this community.โ€ย said Thom Herrmann, CEO of Intuitive Health. โ€œOur philosophy is built on a patient-centric perspective where patients are โ€˜wowedโ€™ at every point in their journey.โ€

The location is open 24-hours a day, seven days a week,ย and is staffed with board-certified physicians and advanced practitioners.ย The urgent care services are available from 7 a.m. โ€“ 9 p.m. and emergency room services are open 24 hours a day.

HOPCo Partners with Future Health Works to Acquire Musculoskeletal Patient Engagement and Outcomes Tracking Platform

acquired

Healthcare Outcomes Performance Company (HOPCo), the US leader in musculoskeletal (MSK) physician practice management, outcomes management, and value-based care solutions, has announced the acquisition of MSK-specific technology platforms developed by London based Future Health Works (FHW), includingย msk.ai.ย  This partnership will dramatically streamline the rollout of evidence-based protocols, automated clinical decision support, remote care management, and value-based care programs.ย  FHW’s innovative software has unique capabilities that include remote patient monitoring (RPM) with real-time patient feedback, artificial intelligence, computer vision, and patented motion capture technology.ย  These platforms, such as myrecovery, have been the preferred patient engagement program for organizations across the UK, including leading Hospitals and Integrated Care Systems (ICSs) within the NHS (National Health Service), provider groups, and implant manufacturers, to provide insights into MSK care, drive improved clinical outcomes, and elevate patient experience and engagement.

“The FHW platforms and their AI capabilities combined with HOPCo’s outcomes management infrastructure will make the transition from volume-based to value-based care easier and more predictable,” said Dr. Wael Barsoum, President and Chief Transformation Officer of HOPCo. “At the same time, providers require more advanced tools to monitor, track, and report outcomes in real-time as part of their participation in value-based care programs.ย  The myrecovery andย msk.aiย platforms impressed us because the engagement rates of patients and providers were dramatically higher than any other platforms we have ever studied and tested.”

FHW’s platforms include a full suite of predictive analytics capabilities that serve as an early identifier of patients at higher risk for adverse outcomes or hospital readmissions.ย  This technology bolsters HOPCo’s already robust outcomes management platform, claims analytics, clinical datasets, and IT tools that have successfully improved clinical outcomes, patient experience, and access to care while lowering the total cost of MSK care and decreasing the historic spending trends for payors across wide geographies.

“Over the last 15 years, HOPCo has had unmatched success in value-based MSK care delivery programs and will continue to do so,” said Dr. Bryan Wall, CMIO at HOPCo. “This acquisition further accelerates HOPCo’s ability to connect patients, providers, and payors, thus enhancing visibility to evidence-based pathways.ย  All of this leads to improved outcomes and savings in a much more meaningful way than other solutions.ย  This also helps HOPCo continue to become the global leader in musculoskeletal complex data management.

HOPCo is currently partnered with health systems and physicians in more than 30 states and continues to partner with payors across the US in advanced value-based care programs, including the country’s first statewide MSK-focused population health program in Arizona.ย  With the addition of the FHW platform, HOPCo is creating an unparalleled technology infrastructure that offers comprehensive analytics and care enhancement services to health systems, physician practices, payors, and patients across the US.

“By leveraging HOPCo’s infrastructure and proven track record of combining data, technologies, and clinical care delivery expertise that unlocks better outcomes and value in the MSK space, FHW can remain focused on our core competencies and accelerate the further development of patient-centric, value-based, care delivery technology solutions,” said Dr. Thomas Harte, CEO and co-founder of FHW. ย “We are excited to have the support and expertise of HOPCo to ensure we replicate in the US the success we have had in the UK and elsewhere.”

This cross-border deal was facilitated and managed by MedWorld Advisors, a leading MedTech/ Healthcare specialized M&A Advisory Firm based in the United States, with offices and partners around the world.

A Closer Look at the Benefits of Long-Term Care Insurance

A Closer Look at the Benefits of Long-Term Care Insurance

As people age, the chances of developing a chronic health condition or needing assistance with activities of daily living (ADLs) increase. According to the U.S. Department of Health and Human Services, approximately 70% of people over age 65 will require some type of long-term care during their lifetimes. Here is a closer look at the benefits of long-term care insurance.

1. Financial protection

One of the main benefits of long-term care insurance is that it can help protect your finances in the event that you need extended care. Long-term care can be very expensive, and if you don’t have insurance, you may have to pay for it all out of pocket. There is long-term care insurance widely available, and it can be very affordable, especially if you purchase it when you are younger. Additionally, many employer-sponsored health insurance plans now offer long-term care insurance as an option. If you have an existing long-term care policy, you should make sure that it is still in force and that the premiums are up to date. It’s important to review your coverage annually, as plan terms and policy conditions may change over time.

2. Peace of mind

Long-term care insurance can also provide peace of mind knowing that you are prepared financially for the future. Many people worry about how they will pay for long-term care if they need it, and this type of insurance can help ease those worries. It’s important to remember that long-term care needs can arise unexpectedly, so it’s important to be prepared ahead of time. Additionally, if you have a family history of chronic health conditions or disabilities, long-term care insurance can be an especially important consideration. It’s vital to speak with your insurance agent and do some research to determine which type of policy is right for you.

3. Access to quality care

One of the biggest benefits of long-term care insurance is that it can help you gain access to high-quality care. If you need extended care, long-term care insurance can help cover the costs of home health aides, nursing homes, assisted living facilities, and other types of care. This type of insurance can also help cover the costs of special equipment or renovations that may be necessary to make your home more accessible. Long-term care insurance can give you peace of mind knowing that you will be able to get the care you need if you ever need it.

4. Tax benefits

Another benefit of long-term care insurance is that it can provide some tax advantages. In general, the premiums that you pay for long-term care insurance are considered tax-deductible medical expenses. Additionally, if your policy pays out benefits, they are usually not taxable. Speak with your tax advisor to determine if you are eligible for any tax benefits. If you are self-employed, you may be able to deduct your long-term care insurance premiums from your taxes. This can help lower your overall tax liability and save you money in the long run. It’s important to speak with your tax advisor to determine if this is a good option for you.

5. Flexibility

Long-term care insurance policies are very flexible, and you can tailor them to meet your specific needs. You can choose the type of coverage you need, the benefits you want, and the length of time you need it. Additionally, you can choose to have your policy cover both home care and nursing home care. This flexibility gives you the ability to design a policy that meets your unique needs and budget. If you have a specific long-term care need in mind, you can even purchase a policy that covers only that type of care. This can help you save money on premiums and get the coverage you need. It’s important to speak with your insurance agent and do some research to determine which type of policy will work best for you.

6. Portability

Another benefit of long-term care insurance is that it is portable. This means that you can take your policy with you if you move to a new location or change jobs. If you are switching employers, you can even purchase a new policy through your employer’s health insurance plan. Long-term care insurance can provide much-needed financial assistance and help ensure that you get the care you need when you need it most. Whether in the form of home care or nursing home care, long-term care insurance can be an invaluable resource for families facing these challenges. With so many benefits available, this type of insurance is definitely worth considering for your future!

7. Protection from increased costs

Long-term care insurance can offer protection from rising costs. As health care and long-term care continue to become increasingly expensive, it’s important to find ways to offset these costs. With long-term care insurance, you can rest assured knowing that your premiums will not increase over time and the quality of your coverage will remain the same. Additionally, many policies include a provision that allows you to adjust your benefits if your health needs change over time. This ensures that you can get the care you need while staying within budget. If you are looking for a way to protect yourself against unexpected future health problems, long-term care insurance is definitely worth considering!

8. You are in control

Finally, long-term care insurance gives you the ability to be in control of your care. With this type of policy, you can choose the provider you want and for how long you need it. This flexibility is very important, as it allows you to get the exact level of care you need. It’s also important to remember that with long-term care insurance, you are not relying on government benefits or family members to provide your care. You are in control of your own destiny and can make sure that you get the care you need when you need it most. It’s a great way to ensure that you are prepared for the future and can maintain your quality of life.

Long-term care insurance can provide many benefits and help ensure that you are prepared for the future. It’s important to speak with your insurance agent and do some research to determine which type of policy will work best for you. With so many options available, you can find a policy that meets your needs and budget. Don’t wait until it’s too late, get long-term care insurance.

Translate ยป